Magnetic resonance imaging and spectroscopy of transgenic models of cancer

NMR in Biomedicine

Volumn 20, Issue 3, 2007, Pages 186-199

  Raman, Venu ^a   Pathak, Arvind P ^a   Glunde, Kristine ^a   Artemov, Dmitri ^a   Bhujwalla, Zaver M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoxia; Metabolism; Molecular imaging; MRI S; Receptor expression; Transgenic models of cancer

Indexed keywords

GENETIC ENGINEERING; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; NONINVASIVE MEDICAL PROCEDURES;

MOLECULAR IMAGING; NON-INVASIVE PHENOTYPING; TRASNGENE TECHNOLOGY;

ONCOLOGY;

ANTIBIOTIC G 418; BLASTICIDIN S; CAPECITABINE; CHOLINE; CRE RECOMBINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUCYTOSINE; FLUOROURACIL; GENOMIC DNA; HYGROMYCIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; NEOMYCIN; PHOSPHORYLCHOLINE; PROTEIN P53; PUROMYCIN; SMALL INTERFERING RNA; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN A;

ANTIBIOTIC RESISTANCE; CANCER CELL; CANCER INVASION; CANCER RESEARCH; CANCER STAGING; CONTRAST ENHANCEMENT; DNA SEQUENCE; DRUG EFFICACY; EMBRYONIC STEM CELL; GENE EXPRESSION REGULATION; GENE MUTATION; GENE OVEREXPRESSION; GENE TARGETING; GENE VECTOR; GENETIC SELECTION; GENETIC TRANSFECTION; GENETIC TRANSFORMATION; KNOCKOUT MOUSE; MAGNETIC RESONANCE ANGIOGRAPHY; MALIGNANT TRANSFORMATION; METASTASIS POTENTIAL; MICROINJECTION; MOLECULAR CLONING; MOLECULAR DYNAMICS; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION; TRANSGENIC MOUSE; TRANSGENICS; TUMOR XENOGRAFT;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; SPECTRUM ANALYSIS;

MUS; MUS MUSCULUS;

EID: 34249747982     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1136     Document Type: Review

References (107)

1. Meade TJ, Taylor AK, Bull SR. New magnetic resonance contrast agents as biochemical reporters. Curr Opin Neurobiol 2003; 13: 597-601
2. Glaser S, Anastassiadis K, Stewart AF. Current issues in mouse genome engineering. Nat Genet 2005; 37: 1187-1193.
3. Miller G. Genetics. Mouse with human chromosome should boost Down syndrome research. Science 2005; 309: 1975.
4. Ikeya M, Kawada M, Nakazawa Y, Sakuragi M, Sasai N, Ueno M, Kiyonari H, Nakao K, Sasai Y. Gene disruption/knock-in analysis of mON T3: vector construction by employing both in vivo and in vitro recombinations. Int J Dev Biol 2005; 49: 807-823.
5. Prasad V, Okunade GW, Miller ML, Shull GE. Phenotypes of SERCA and PMCA knockout mice. Biochem Biophys Res Commun 2004; 322: 1192-1203.
6. Abdulkadir SA, Kim J. Genetically engineered murine models of prostate cancer: insights into mechanisms of tumorigenesis and potential utility. Future Oncol 2005; 1: 351-360.
7. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs: will they model the next 100? Nat Rev Drug Discov. 2003; 2: 38-51.
8. Heck S, Qian X, Velleca M. Genetically engineered mouse models for drug discovery: new chemical genetic approaches. Curr Drug Discov Technol 2004; 1: 13-26.
9. Cespedes MV, Casanova I, Parreno M, Mangues R. Mouse models in oncogenesis and cancer therapy. Clin Transl Oncol 2006; 8: 318-329.
10. Hennighausen L. Mouse models for breast cancer. Oncogene 2000; 19: 966-967.
11. Hennighausen L. Mouse models for breast cancer. Breast Cancer Res 2000; 2: 2-7.
12. Kim JB, O'Hare MJ, Stein R. Models of breast cancer: is merging human and animal models the future? Breast Cancer Res 2004; 6: 22-30.
13. Wagner KU. Models of breast cancer: quo vadis, animal modeling? Breast Cancer Res 2004; 6: 31-38.
14. Twentyman PR, Brown JM, Gray JW, Franko AJ, Scoles MA, Kallman RF. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 1980; 64: 595-604.
15. Rockwell SC, Kallman RF, Fajardo LF. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 1972; 49: 735-749.
16. Cardiff RD, Rosner A, Hogarth MA, Galvez JJ, Borowsky AD, Gregg JP. Validation: the new challenge for pathology. 2004; Toxicol Pathol 32(Suppl 1): 31-39.
17. Recillas-Targa F. Gene transfer and expression in mammalian cell lines and transgenic animals. Methods Mol Biol 2004; 267: 417-433.
18. Chu G, Hayakawa H, Berg P. Electroporation for the efficient transfection of mammalian cells with DNA. Nucleic Acids Res 1987; 15: 1311-1326.
19. Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7417.
20. Horst J, Kluge E Beyreuther K, Gerok W. Gene transfer to human cells: transducing phage lambda plac gene expression in GMI-gangliosidosis fibroblasts. Proc Natl Acad Sci USA 1975; 72: 3531-3535.
21. Winnard P, Jr., Mironchik Y, Raman V. Robust expression of transgenes in MCF-7 breast cancer cells is expression vector-dependent. Biotechniques 2004; 37: 370, 372, 374.
22. Zhu Z, Zheng T, Lee CG, Homer RJ, Elias JA. Tetracycline-controlled transcriptional regulation systems: advances and application in transgenic animal modeling. Semin Cell Dev Biol 2002; 13: 121-128.
23. Liu HS, Lee CH, Lee CE Su IJ, Chang TY. Lac/Tet dual-inducible system functions in mammalian cell lines. Biotechniques 1998; 24: 624-628, 630-632.
24. Loser P, Jennings GS, Strauss M, Sandig V. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
25. Allamane S, Ratel D, Jourdes P, Berger F, Benabid AL, Wion D. p53 Status and gene transfer experiments using CMV enhancer/promoter. Biochem Biophys Res Commun 2001; 280: 45-47.
26. Chen YJ, Chen WS, Wu TY. Development of a bi-cistronic baculovirus expression vector by the Rhopalosiphum padi virus 5′ internal ribosome entry site. Biochem Biophys Res Commun 2005; 335: 616-623.
27. Amendola M, Venneri MA, Biffi A, Vigna E, Naldini L. Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 2005; 23: 108-116.
28. Caceres G, Zhu XY, Jiao JA, Zankina R, Aller A, Andreotti P. Imaging of luciferase and GFP-transfected human tumours in nude mice. Luminescence 2003; 18: 218-223.
29. Morris KV. Therapeutic potential of siRNA-mediated transcriptional gene silencing. 2006; BiotechniquesSuppl: 7-13.
30. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 2003; 270: 1628-1644.
31. Bunz F. Human cell knockouts. Curr Opin Oncol 2002; 14: 73-78.
32. Aylon Y, Kupiec M. New insights into the mechanism of homologous recombination in yeast. Mutat Res 2004; 566: 231-248.
33. Ohlfest JR, Freese AB, Largaespada DA. Nonviral vectors for cancer gene therapy: prospects for integrating vectors and combination therapies. Curr Gene Ther 2005; 5: 629-641.
34. Chan AW. Transgenie animals: current and alternative strategies. Cloning 1999; 1: 25-46.
35. Auerbach AB. Production of functional transgenic mice by DNA pronuclear microinjection. Acta Biochim Pol 2004; 51: 9-31.
36. Downing GJ, Battey JF, Jr, Technical assessment of the first 20 years of research using mouse embryonic stem cell lines. Stem Cells 2004; 22: 1168-1180.
37. Gossen JA, de Leeuw WJ, Vijg J. LacZ transgenic mouse models: their application in genetic toxicology. Mutat Res 1994; 307: 451-459.
38. Weber W, Fussenegger M. Inducible gene expression in mammalian cells and mice. Methods Mol Biol 2004; 267: 451-466.
39. Hadjantonakis AK, Dickinson ME, Fraser SE, Papaioannou VE. Technicolour transgenics: imaging tools for functional genomics in the mouse. Nat Rev Genet 2003; 4: 613-625.
40. Ikawa M, Yamada S, Nakanishi T, Okabe M. 'Green mice' and their potential usage in biological research. FEBS Lett 1998; 430: 83-87.
41. Saito S, Liu B, Yokoyama K. Animal embryonic stem (ES) cells: self-renewal, pluripotency, transgenesis and nuclear transfer. Hum Cell 2004; 17: 107-115.
42. Lerou PH, Daley GQ. Therapeutic potential of embryonic stem cells. Blood Rev 2005; 19: 321-331.
43. Ralston A, Rossant J. Genetic regulation of stem cell origins in the mouse embryo. Clin Genet 2005; 68: 106-112.
44. Trounson A. Derivation characteristics and perspectives for mammalian pluripotential stem cells. Reprod Fertil Dev 2005; 17: 135-141.
45. Ristevski S. Making better transgenic models: conditional, temporal, and spatial approaches. Mol Biotechnol 2005; 29: 153-163.
46. Davies BR, Warren JR, Schmidt G, Rudland PS. Induction of a variety of preneoplasias and tumours in the mammary glands of transgenic rats. Biochem Soc Symp 1998; 63: 167-184.
47. Lipnik K, Petznek H, Renner-Muller I, Egerbacher M, Url A, Salmons B, Gunzburg WH, Hohenadl C. A 470bp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice. Transgenic Res 2005; 14: 145-158.
48. Clark AJ. Gene expression in the mammary glands of transgenic animals. Biochem Soc Symp 1998; 63: 133-140.
49. Ghoshal K, Jacob ST. Regulation of metallothionein gene expression. Prog Nucleic Acid Res Mol Biol 2001; 66: 357-384.
50. Kos CH. Cre/loxP system for generating tissue-specific knockout mouse models. Nutr Rev 2004; 62: 243-246.
51. Stricklett PK, Nelson RD, Kohan DE. The Cre/loxP system and gene targeting in the kidney. Am J Physiol 1999; 276: F651-657.
52. Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet 2001; 2: 743-755.
53. Garcia-Otin AL, Guillou F. Mammalian genome targeting using site-specific recombinases. Front Biosci 2006; 11: 1108-1136.
54. Brodie SG, Deng CX. BRCA1-associated tumorigenesis: what have we learned from knockout mice? Trends Genet 2001; 17: S18-22.
55. Vooijs M, Berns A. Developmental defects and tumor predisposition in Rb mutant mice. Oncogene 1999; 18: 5293-5303.
56. Blackburn AC, Jerry DJ. Knockout and transgenic mice of Trp53: what have we learned about p53 in breast cancer? Breast Cancer Res 2002; 4: 101-111.
57. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 2006; 20: 1496-1510.
58. Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005; 64: 224-239.
59. Abdulkadir SA, Qu Z, Garabedian E, Song SK, Peters TJ, Svaren J, Carbone JM, Naughton CK, Catalona WJ, Ackerman JJ, Gordon JI, Humphrey PA, Milbrandt J. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med 2001; 7: 101-107.
60. Bock NA, Zadeh G, Davidson LM, Qian B, Sled JG, Guha A, Henkelman RM. High-resolution longitudinal screening with magnetic resonance imaging in a murine brain cancer model. Neoplasia 2003; 5: 546-554.
61. Song SK, Qu Z, Garabedian EM, Gordon JI, Milbrandt J, Ackerman JJ. Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res 2002; 62: 1555-1558.
62. Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW. Micro-magnetic resonance lymphangiography in mice using a novel dendrimer-based magnetic resonance imaging contrast agent. Cancer Res 2003; 63: 271-276.
63. Brubaker LM, Bullitt E, Yin C, Van Dyke T, Lin W. Magnetic resonance angiography visualization of abnormal tumor vasculature in genetically engineered mice. Cancer Res 2005; 65: 8218-8223.
64. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
65. Bhujwalla ZM, Artemov D, Natarajan K, Ackerstaff E, Solaiyappan M. Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts. Neoplasia 2001; 3: 143-153.
66. Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-1857.
67. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69(Suppl 3): 4-10.
68. Dafni H, Israely T, Bhujwalla ZM, Benjamin LE, Neeman M. Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin. Cancer Res 2002; 62: 6731-6739.
69. Bhujwalla ZM, Raman V, Artemov D, Mironchik Y, Kolars P, Pathak AP, Solaiyappan M. MRI of prostate tumors overexpressing VEGF exhibit distinct alterations of vascular permeability. In Proceedsings of the International Society of Magnetic Resonance Medsicine 2003.
70. Pathak AP, Gimi B, Glunde K, Ackerstaff E, Artemov D, Bhujwalla ZM. Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol 2004; 386: 3-60.
71. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. 2000; Nat Med 6: 351-355.
72. Artemov D, Mori N, Okollie B, Bhujwalla ZM. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med 2003; 49: 403-408.
73. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res 2003; 63: 2723-2727.
74. Komar AA, Hatzoglou M. Internal ribosome entry sites in cellular mRNAs: mystery of their existence. J Biol Chem 2005; 280: 23425-23428.
75. McMahon MT, Gilad AA, Zhou J, Sun PZ, Bulte JW, van Zijl PC. Quantifying exchange rates in chemical exchange saturation transfer agents using the saturation time and saturation power dependencies of the magnetization transfer effect on the magnetic resonance imaging signal (QUEST and QUESP): Ph calibration for poly-L-lysine and a starburst dendrimer. Magn Reson Med 2006; 55: 836-847.
76. Aime S, Delli Castelli D, Terreno E. Supramolecular adducts between poly-L-arginine and [TmIIIdotp]: a route to sensitivity-enhanced magnetic resonance imaging-chemical exchange saturation transfer agents. Angew Chem Int Ed Engl 2003; 42: 4527-4529.
77. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. Neoplasia 2005; 7: 109-117.
78. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5: 303-324.
79. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12: 413-439.
80. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001; 3: 36-40.
81. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 2003; 90: 525-533.
82. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br J Cancer 2001; 84: 691-696.
83. Teegarden D, Taparowsky EJ, Kent C. Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene. J Biol Chem 1990; 265: 6042-6047.
84. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K. Oncogene 2002; 21: 937-946.
85. Ratnam S, Kent C. Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines. Arch Biochem Biophys 1995; 323: 313-322.
86. Momchilova A, Markovska T, Pankov R. Ha-ras-transformation alters the metabolism of phosphatidylethanolamine and phosphatidylcholine in NIH 3T3 fibroblasts. Cell Biol Int 1999; 23: 603-610.
87. Lucas L, Penalva V, Ramirez de Molina A, Del Peso L, Lacal JC. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int J Oncol 2002; 21: 477-485.
88. Podo F, Ferretti A, Knijn A, Zhang P, Ramoni C, Barletta B, Pini C, Baccarini S, Pulciani S. Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res 1996; 16: 1399-1412.
89. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999; 59: 80-84.
90. Rodrigues LM, Stubbs M, Robinson SP, Newell B, Mansi J, Griffiths JR. The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods. Magma 2004; 17: 260-270.
91. Mori N, Delsite R, Natarajan K, Kulawiec M, Bhujwalla ZM, Singh KK. Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging 2004; 3: 319-323.
92. Bhujwalla ZM, Aboagye EO, Gillies RJ, Chacko VP, Mendola CE, Backer JM. Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn Reson Med 1999; 41: 897-903.
93. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378.
94. Ramirez de Molina A, Gutierrez R, Ramos MA, Silva JM, Silva J, Bonilla F, Sanchez JJ, Lacal JC. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21: 4317-4322.
95. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002; 296: 580-583.
96. Nakagami K, Uchi T, Ohwada S, Koibuchi Y, Morishita Y. Increased choline kinase activity in 1,2-dimethylhydrazine-induced rat colon cancer. Jpn J Cancer Res 1999; 90: 1212-1217.
97. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Suda Y, Sekine T, Morishita Y. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res 1999; 90: 419-424.
98. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004; 64: 4270-4276.
99. Glunde K, Raman V, Mori N, Bhujwalla ZM. RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res 2005; 65: 11034-11043.
100. Stegman LD, Rehemtulla A, Beattie B, Kievit E, Lawrence TS, Blasberg RG, Tjuvajev JG, Ross BD. Noninvasive quantitation of cytosine deaminase transgene expression in human tumor xenografts with in vivo magnetic resonance spectroscopy. Proc Natl Acad Sci USA 1999; 96: 9821-9826.
101. Chung YL, Troy H, Judson IR, Leek R, Leach MO, Stubbs M, Harris AL, Griffiths JR. Noninvasive measurements of capecitabine metabolism in bladder tumors overexpressing thymidine phosphorylase by fluorine-19 magnetic resonance spectroscopy. Clin Cancer Res 2004; 10: 3863-3870.
102. Raman V, Artemov D, Pathak AP, Winnard PT, Jr., McNutt S, Yudina A, Bogdanov A, Jr., Bhujwalla ZM. Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 2006; 66: 9929-9936.
103. Semenza GL. Regulation of physiological responses to continuous and intermittent hypoxia by hypoxia-inducible factor 1. Exp Physiol 2006; 91: 803-806.
104. Semenza GL, Shimoda LA, Prabhakar NR. Regulation of gene expression by HIF-1. Novartis Found Symp 2006; 272: 2-8; discussion 8-14, 33-36.
105. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000; 7: 493-498.
106. Cherry SR. Multimodality in vivo imaging systems: twice the power or double the trouble? Annu Rev Biomed Eng 2006; 8: 35-62. DOI: 10. 1146/annurev.bioeng.8.061505.095728.
107. Kato Y, Okollie B, Artemov D. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn Reson Med 2006; 55: 755-761.